ClinicalTrials.gg
SuspendedNCT06723171Updated Nov 12, 2026

Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis

A Phase 2 interventional study of IRX4204 and Placebo in Psoriasis, Plaque Type Psorisis and Plaque Psoriasis, sponsored by Io Therapeutics. Suspended at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Io Therapeutics · Phase 2, Interventional, and Treatment

Why this study was suspended
Sponsor request for study hold, funding issues
Updated Nov 12, 2026Reason for stopping updatedStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.

Planned enrollment
545th of 673
20 · median 77
Started
2027
with 1 other
Phase 2
200 of 764
5 open now
Registered
727th of 764
by date

Among the 764 studies in Psoriasis with a site in United States, this one is the 545th largest by planned enrollment of the 673 interventional ones that give a count, is one of 2 that started in 2027, is one of 200 in phase 2, and was the 727th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 764 studies in Psoriasis with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if IRX4204 works to treat plaque psoriasis in adults. It will also learn about the safety of IRX4204. The main questions it aims to answer are:

  • Does IRX4204 treat plaque psoriasis symptoms?
  • Does IRX4204 treat plaque psoriasis symptoms better than someone who is not being treated?
  • What medical problems do participants have when taking IRX4204?

Researchers will compare IRX4204 to a placebo (a look-alike substance that contains no drug) to see if the drug works to treat mild to moderate plaque psoriasis.

Participants will:

  • Take IRX4204 every day for 28 days
  • Visit the clinic once every week for checkups and tests
  • Complete specific assessments about plaque psoriasis and changes to plaques
03

Conditions studied

  • Psoriasis
  • Plaque Type Psorisis
  • Plaque Psoriasis

Browse trials for

Keywords

  • RXR
  • Psoriasis
  • plaque psoriasis
  • plaques
  • mild psoriasis
  • IRX4204
  • IO Therapeutics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years of age
  2. Have a diagnosis of plaque psoriasis (with or without psoriatic arthritis) for at least 6 months before the first administration of study treatment
  3. Meet the following disease severity criteria for moderate to severe plaque psoriasis at Screening and Baseline visits:

    1. IGA Score of 3 or 4 AND
    2. Total affected body surface area of >3 to 10% for moderate and 10% to 15% for severe psoriasis
    3. Excludes participants with scalp only plaques
  4. Be inadequately controlled with or intolerant of at least one prior topical therapy including but not limited to: , retinoids, vitamin D, vitamin D/steroid and retinoid/steroid combinations, tacrolimus, pimecrolimus, anthralin/dithranol, coal tar preparations, tapinarof, roflumilast for the treatment of psoriasis at both Screening and Baseline visits
  5. In the opinion of the Investigator, be a candidate for phototherapy or systemic treatment for psoriasis
  6. Completed appropriate washouts for prior treatments for psoriasis
  7. Be considered, in the opinion of the Investigator, suitable candidates for RXR agonist therapy
  8. Women participants of (WOCBP) (see Section 8.1.10) or sexually active male participants with partners of childbearing potential agree to practice a highly effective method of (failure rate of \< 1% per year when used consistently and correctly; see Section 8.1.10.1) prior to receiving, while receiving, and for at least 6 months after receiving the last administration of study intervention
  9. WOCBP must have a negative highly sensitive serum beta-human chorionic gonadotropic (b-hCG) pregnancy test at Screening and confirmed at Baseline prior to receiving the first administration of study drug
  10. WOCBP must agree not to donate eggs (ova, oocytes) or freeze for future and males must agree not to donate sperm for the purpose of reproduction for at least 6 months after receiving the last administration of study intervention.
  11. Female participants must agree to not breastfeed while enrolled in this study and within 6 months after the last dose of study intervention
  12. Sign an form (ICF) indicating that the participant understands the purpose of, and procedures required for, the study and is willing to participate in the study
  13. Be willing to and able to adhere to the requirements in this protocol

Exclusion criteria

Exclusion Criteria:

  1. Has more than 15% of total body surface area affected by psoriasis plaques
  2. Has a non-plaque form of psoriasis (e.g., erythrodermic, guttate, or pustular) at Screening or at time of randomization
  3. Has current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta-blockers, calcium channel blockers, or lithium)
  4. Has confounding diagnoses including but not limited to palmoplantar pustulosis, eczematous dermatitis, contact/irritant dermatitis, acquired keratoderma
  5. Has received within 12 weeks of the first dose (Day 1) any prior biologic (or biosimilars of) for the treatment of psoriasis, psoriatic arthritis, or any other indications that could impact the assessment of psoriasis. Prior biologic therapy includes but is not limited to TNF-inhibitors, IL-17 inhibitors, IL-12/23 inhibitors, IL-23 inhibitors
  6. Has received within 4 weeks of the first dose (Day 1) any systemic immunosuppressives for the treatment of psoriasis or psoriatic arthritis, or any other indications that could impact the assessment of psoriasis, Phototherapy or narrow band laser (e.g., Excimer or XTRAC), lithium, antimalarials, or intramuscular (IM) gold. Systemic therapy includes but is not limited to methotrexate, azathioprine, cyclosporine, JAK/TYK pathway inhibitors, 6-thioguanine, mercaptopurine, mycophenolate mofetil, tacrolimus, acitretin, or anakinra
  7. Has received within 2 weeks of the first dose (Day 1) any topical medications for psoriasis or other conditions that could impact assessment of psoriasis, including but not limited to topical , retinoids, vitamin D analogs, combinations of calcipotriene and topical corticosteroids, tacrolimus, pimecrolimus, anthralin/dithranol, coal tar preparations, PDE4 inhibitors (e.g. crisaborole), or other topicals used for the treatment of psoriasis (tapinarof, roflumilast etc.)
  8. Has received within 12 weeks or 5 half-lives (whichever is longer) of the first dose (Day 1) other biologic therapy or experimental antibody, any agent that modulates T-cells (e.g., natalizumab, abatacept etc.)
  9. Has received within 4 weeks or 5 half-lives (whichever is longer) of the first dose (Day 1) any other experimental systemic therapy for any indication
  10. Is currently enrolled in another study using an agent or procedure
  11. Has evidence of skin conditions that could interfere with clinical assessments of psoriasis (e.g. eczema, seborrheic dermatitis, or pityriasis rosea)
  12. Has a current history of severe, uncontrolled or progressive systemic medical conditions including renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
  13. Has unstable cardiovascular disease, defined as a recent clinical deterioration in the last 3 months (e.g., unstable angina, atrial fibrillation) or a cardiac hospitalization within the last 3 months
  14. Currently has a known or has a history of malignancy within 5 years before screening with the exception of non-melanoma skin cancer curatively treated with no evidence of recurrence for at least 3 months before the first study drug administration or cervical carcinoma in situ of the cervix that has been treated with no evidence of recurrence for at least 3 years before the first study drug administration
  15. Has a history of lymphoproliferative disease, including lymphoma, leukemia, monoclonal gammopathy, or signs/symptoms suggestive of possible lymphoproliferative disease
  16. Has a transplanted organ (with the exception of a corneal transplant > 3 months before the first study drug administration)
  17. Has unstable suicidal ideation or suicidal behavior, or a suicide attempt (including interrupted, aborted attempts and preparatory behaviors for suicide attempt), in the last 6 months
  18. Has had a major surgery within 8 weeks of Screening or has such surgery planned during the time participant is expected to participate in the study
  19. Has had a substance abuse problem within the previous 12 months
  20. Has a history of chronic or recurrent infectious disease including but not limited to chronic renal infection, recurrent urinary tract infection (UTI), chronic respiratory infections (e.g., tuberculosis), skin infections, or fungal infections
  21. Is currently being treated for a thyroid condition or have abnormalities in TSH, free T4 or T3 at Screening
  22. Has had a serious infection (e.g., sepsis, pneumonia, pyelonephritis) requiring hospitalization within the 2 months before Screening
  23. Has had herpes zoster (shingles) within 2 months prior to Screening
  24. Has an active tuberculosis (TB) infection as confirmed by TB test during screening
  25. Tests positive for virus (HBV) infection
  26. Is seropositive for antibodies to virus (HCV). If the antibody test result is positive at screening, the participant will be allowed to be re-screened one time and enrolled after a negative HCV RNA test result
  27. Is infected with (HIV)
  28. Unable to avoid prolonged sun exposure or use of tanning beds or other ultraviolet light sources
  29. Has received within 2 weeks of the first dose (Day 1) any prescribed anticoagulant, including but not limited to coumarins (such as warfarin), factor Xa inhibitors (i.e., apixaban, rivaroxaban), heparins (e.g., heparin, enoxaparin), and direct thrombin inhibitors
  30. Has any condition that, in the opinion of the Investigator, would make participation not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments
  31. Is an employee of the Investigator or study site, with direct involvement in the proposed study or other studies under the direction of that Investigator or study site, as well as family members of the employees or the Investigator
  32. Any abnormal laboratory value greater than 2.5 times (ULN). If one or more of the laboratory parameters is out of range, a single retest of laboratory values is permitted
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    Treatment

    IRX4204

    Drug: IRX4204

  • Placebo comparator
    Placebo

    Placebo

    Other: Placebo

Interventions

  • Active Treatment

    Also known as: IRX4204Psoriasis, NRX194204

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. To evaluate if participants receiving IRX4204 achieve greater reduction in IGA scores when compared to participants receiving placebo

    Percentage of participants achieving an Investigator's Global Assessment (IGA) score of clear (0) or almost clear (1) at Day 28 with at least a 2-grade improvement from Baseline to end of study.

    Time frame: Baseline (Day 1) to Day 42

Secondary outcomes

  1. To evaluate if participants receiving IRX4204 have greater improvement in participant reported outcomes when compared to participants receiving placebo

    Change in Daily Quality of Life Index (DLQI) score will be evaluated. The DLQI is calculated by adding the score of each question, resulting in a minimum of 0 to a maximum of 30. The higher the score, the more quality of life is impaired.

    Time frame: from Baseline (Day 1) to Day 28

  2. To evaluate if participants receiving IRX4204 experience a greater reduction in affected Body Surface Area when compared to participants receiving placebo

    Percent change in affected Body Surface Area (BSA) from Baseline to end of treatment will be evaluated. The body surface area refers to the total amount of skin on the body that is covered by psoriasis lesions and used to assess the severity of the condition. A higher percentage indicates a more severe case of psoriasis.

    Time frame: from Baseline (Day 1) to Day 28

  3. To evaluate if a greater proportion of participants receiving IRX4204 achieve PASI50, PASI75 and PASI90 when compared to participants receiving placebo

    Proportion of participants to achieve PASI50 (50% or greater improvement from Baseline), PASI75, and PASI90 to the end of the study will be evaluated. Achieving PASI 50, PASI 75, and PASI 90 indicates different levels of improvement in psoriasis severity as measured by the Psoriasis Area and Severity Index (PASI) score, with PASI 50 indicating a 50% reduction from baseline, PASI 75 signifying a 75% reduction, and PASI 90 representing a 90% reduction in psoriasis symptoms. Higher PASI numbers signifying increasingly clearer skin.

    Time frame: from Baseline (Day 1) to End of Study (Day 42)

  4. To evaluate if participants receiving IRX4204 achieve greater improvement from baseline in disease and symptom severity as measured by the Psoriasis Area and Severity Index (PASI).

    Change From Baseline to Day 28 in mean Psoriasis Area and Severity Index (PASI) score of participants receiving IRX4204 compared to placebo.

    Time frame: from Baseline (Day 1) to End of Treatment (Day 28)

Other outcomes

  1. Incidence of Treatment Emergent and Serious Adverse Events

    The number of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), and the number of participants who experienced TEAEs and SAEs will also be tabulated to evaluate the safety profile of IRX4204.

    Time frame: from Baseline (Day 1) to End of Study (Day 42)

07

Study locations

1 site
  • Not posted
    Webster, Texas 77598, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Mar 2027; primary completion for Dec 2027, 9 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Mar 2026 → Mar 2027, primary completion Mar 2026 → Dec 2027 and completion Apr 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2024
First posted
Dec 9, 2024
StartEst.
Mar 1, 2027was Mar 2026
Primary completionEst.
Dec 2027was Mar 2026
CompletionEst.
Dec 2027was Apr 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Why stopped
Sponsor request for study hold, funding issues
Nov 12, 2026
Start date
Mar 1, 2026→Mar 1, 2027
Nov 12, 2026
Primary completion
Mar 2026→Dec 2027
Nov 12, 2026
Study completion
Apr 2026→Dec 2027
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Why stopped Sponsor request for study hold, funding issues
    Start date Mar 1, 2026→Mar 1, 2027
    Primary completion Mar 2026→Dec 2027
    Study completion Apr 2026→Dec 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06723171
Lead sponsor
Io Therapeutics
Responsible party
Sponsor
First posted
Dec 9, 2024
Start date
Mar 1, 2027 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AGN 194204

Start the discussion